EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The event will take place on Thursday, August 15th, 2024.

Dr. Jay S. Duker, President and CEO of EyePoint, will present a Company Overview available on-demand from 7:00 a.m. ET. Additionally, he will participate in a panel discussion on 'The Evolving Therapeutic Landscape of AMD' at 9:00 a.m. ET.

Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website. The replay will remain available for 90 days after the event.

WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the H.C. Wainwright 4^th Annual Ophthalmology Virtual Conference:

• Company Overview
  Date: Thursday, August 15^th, 2024
  Time: Available on-demand at 7:00 a.m. ET

• The Evolving Therapeutic Landscape of AMD Panel Discussion
  Date: Thursday, August 15^th, 2024
  Time: 9:00 a.m. ET

A live webcast and subsequent archived replay of the panel and the on-demand company overview may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and diabetic macular edema (DME). EyePoint expects to randomize patients for inclusion in pivotal Phase 3 clinical trials in wet AMD in 2024.

Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert^® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When is EyePoint Pharmaceuticals (EYPT) presenting at the H.C. Wainwright Ophthalmology Conference?

EyePoint Pharmaceuticals (EYPT) is presenting at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15th, 2024. The Company Overview will be available on-demand from 7:00 a.m. ET, and the panel discussion will take place at 9:00 a.m. ET.

What topics will EyePoint Pharmaceuticals (EYPT) discuss at the conference?

EyePoint Pharmaceuticals (EYPT) will present a Company Overview and participate in a panel discussion on 'The Evolving Therapeutic Landscape of AMD' at the H.C. Wainwright Ophthalmology Conference.

How can investors access EyePoint Pharmaceuticals' (EYPT) presentations from the conference?

Investors can access live webcasts and archived replays of EyePoint Pharmaceuticals' (EYPT) presentations through the Investors section of the company's website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

Who will represent EyePoint Pharmaceuticals (EYPT) at the H.C. Wainwright Ophthalmology Conference?

Dr. Jay S. Duker, President and Chief Executive Officer of EyePoint Pharmaceuticals (EYPT), will represent the company at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.